Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride + EBRT vs EBRT in castration-resistant prostate cancer with bone metastases
DRKS00007787Phase 2Terminated
- Sponsor
- Universitätsklinikum Freiburg
- Start
- May 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) and Primary bone malignancy (None.) comparing EBRT + Radium-223 dichloride + best supportive care with EBRT + best supportive care (2 arms). Started May 2015; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)Primary bone malignancy (None.)
Beyond the preview
Go deeper on DRKS00007787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00007787.